Letermovir-Associated Post-Transplant Lymphoproliferative Disorder (USCAP 2026) - Feb 25, 2026 - Pres time: Mar 25, 2026; 09:30 AM - 12:00 PM; Location: Hall 2; Board Number 193; "While our cohort is small, all of the lesions diagnosed in stem cell transplant patients may be classified as nondestructive lesions per International Consensus Classification (ICC) 2022 and hyperplasias arising in immune deficiency/dysregulation per World Health Organization classification 2022, which, per ICC, represent only 5% of PTLD. This may be a trend warranting investigation with larger cohorts. Additionally, the interplay between CMV status and prophylaxis and Epstein-Barr virus in the setting of immunodeficiency remains fertile ground for future investigation."
Post-transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Multiple Myeloma • Transplantation
|
|
Anne Chen, MD; Katherine N. Williams, MD
|